Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
Metacrine, Inc. (Nasdaq: MTCR) will hold a conference call on March 18, 2021, at 8:30 a.m. ET to discuss its Q4 and full-year 2020 financial results. The company specializes in developing therapies for liver and gastrointestinal diseases, with ongoing clinical trials for its product candidates, MET409 and MET642, aimed at treating non-alcoholic steatohepatitis (NASH). MET409 is currently in combination studies, while MET642 has completed Phase 1 trials. Interested parties can join via phone or webcast.
- MET409 has completed a 12-week monotherapy trial for NASH.
- MET642 has completed a 14-day Phase 1 trial with positive outcomes.
- Ongoing evaluations for MET409 in combination trials with empagliflozin.
- None.
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2020 financial results and other business highlights on Thursday, March 18, 2021 at 8:30 a.m. ET.
To participate in the conference call, please dial (833) 614-1526 (domestic) or (520) 809-9922 (international) and refer to conference ID 4995715. A webcast will be available in the investor section of the company's website at www.metacrine.com, and will be archived for 60 days following the call.
About Metacrine
Metacrine, Inc. (Nasdaq: MTCR) is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated a differentiated and improved therapeutic profile in clinical trials. The company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH). MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH.
Contact:
Steve Kunszabo
investors@metacrine.com
FAQ
When will Metacrine announce its Q4 2020 financial results?
What are the product candidates being developed by Metacrine?
How can I participate in the Metacrine conference call?
What is the focus of Metacrine's research?
